Journal Article

Complex I inhibitor of oxidative phosphorylation in advanced solid tumors and acute myeloid leukemia: phase I trials

Yilmaz, Musa, Ohanian, Maro, Jabbour, Elias J., Heffernan, Timothy P., Hong, David S., Dumbrava, Ecaterina E., Kamiya-Matsuoka, Carlos, Pant, Shubham, Bristow, Christopher A., Pemmaraju, Naveen, Subbiah, Vivek, Naing, Aung, Ravandi, Farhad, Konopleva, Marina, Gao, Sisi, Piha-Paul, Sarina A., Salguero, Carolina, Kantarjian, Hagop M., Meric-Bernstam, Funda, Collins, Meghan E., Tsimberidou, Apostolia M., Zhang, Qi, Xu, Quanyun A., Lodi, Alessia, Vellano, Christopher P., Daver, Naval, Zhang, Jixiang, Tiziani, Stefano, Kavelaars, Annemieke, Bose, Prithviraj, Singh, Anand K., Molina, Jennifer R., Rodon, Jordi, Mahendra, Mikhila, Francesco, Maria Emilia Di, Fu, Siqing, Jones, Philip, Sasaki, Koji, Li, Yuan, Marszalek, Joseph R., Bhattacharjee, Meenakshi B., Heijnen, Cobi J., Gera, Sonal, Karp, Daniel D., Baran, Natalia, Han, Jing, Ju, Zhenlin, Gay, Jason P., Yap, Timothy A.

2023

Overview

Although targeting oxidative phosphorylation (OXPHOS) is a rational anticancer strategy, clinical benefit with OXPHOS inhibitors has yet to be achieved. Here we advanced IACS-010759, a highly potent and selective small-molecule complex I inhibitor, into two dose-escalation phase I trials in patients with relapsed/refractory acute myeloid leukemia (NCT02882321, n  = 17) and advanced solid tumors (NCT03291938, n  = 23). The primary endpoints were safety, tolerability, maximum tolerated dose and recommended phase 2 dose (RP2D) of IACS-010759. The PK, PD, and preliminary antitumor activities of IACS-010759 in patients were also evaluated as secondary endpoints in both clinical trials. IACS-010759 had a narrow therapeutic index with emergent dose-limiting toxicities, including elevated blood lactate and neurotoxicity, which obstructed efforts to maintain target exposure. Consequently no RP2D was established, only modest target inhibition and limited antitumor activity were observed at tolerated doses, and both trials were discontinued. Reverse translational studies in mice demonstrated that IACS-010759 induced behavioral and physiological changes indicative of peripheral neuropathy, which were minimized with the coadministration of a histone deacetylase 6 inhibitor. Additional studies are needed to elucidate the association between OXPHOS inhibition and neurotoxicity, and caution is warranted in the continued development of complex I inhibitors as antitumor agents. A mitochondrial complex I inhibitor exhibited dose-limiting toxicities, including neurotoxicity, in patients with acute myeloid leukemia and solid tumors, warranting further studies to evaluate the mechanism linking oxidative phosphorylation inhibition and neurotoxicity.

• Publisher: Nature Publishing Group US,Nature Publishing Group
• Subject: 631/154/1438 / 631/154/570 / 631/67 / 631/67/1059/153 / 631/67/2327 / Acute myeloid leukemia / Animals / Anticancer properties / Antineoplastic Agents - adverse effects / Antitumor activity / Antitumor agents / Biomedical and Life Sciences / Biomedicine / Cancer Research / Clinical trials / Constraining / Electron transport chain / Histone deacetylase / Histone Deacetylase Inhibitors - therapeutic use / Humans / Infectious Diseases / Inhibitors / Kinases / Lactic acid / Leukemia / Leukemia, Myeloid, Acute - drug therapy / Leukemia, Myeloid, Acute - pathology / Metabolic Diseases / Mice / Mitochondria / Molecular Medicine / NADH-ubiquinone oxidoreductase / Neoplasms - pathology / Neurosciences / Neurotoxicity / Oxidative Phosphorylation / Peripheral neuropathy / Phosphorylation / Solid tumors